Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
- Citation:
- PLoS ONE vol 7 (7) e39285
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 1
- Parents:
- 384
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA035267, U10 CA052352, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35090, CA-52352, CA-35195, U10 CA037404, U10 CA035195, CA-35103, CA-25224, P50 CA116201, U10 CA035101, U10 CA063849, U10 CA035431, CA-37417, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103
- Corr. Author:
- Authors:
- Shernan G. Holtan Preston D. Steen Nathan R. Foster Charles Erlichman Fabiola Medeiros Matthew M. Ames Stephanie L. Safgren David L. Graham Robert J. Behrens Matthew P. Goetz
- Networks:
- Study
- NCCTG-N004E
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Research Article, Medicine, Clinical Research Design, Clinical Trials, Phase II, Drugs and Devices, Adverse Reactions, Drug Research and Development, Oncology, Basic Cancer Research, Metastasis, Cancer Treatment, Chemotherapy and Drug Treatment, Clinical Trials (Cancer Treatment), Cancers and Neoplasms, Unknown Primary Cancer